Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer

Jonathan J. Beitler, Scott Wadler, Hilda Haynes-Lewis, Stanley Fell, Alla Rozenblit, Ellen Wolf, Barry A. Levine

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A pilot study was performed to assess the feasibility of combining 5-fluorouracil, recombinant alpha-2b-interferon, external radiation therapy and intraluminal high dose rate brachytherapy with surgery in patients with locally advanced esophageal carcinoma. 5-fluorouracil, 750 mg m-2, was administered via continuous 5-day infusion beginning day 1 and weekly thereafter; interferon, 10 mu subcutaneously, was administered three times per week beginning day 1 and sargramostin, 5 μg kg-1, was administered on days without 5-fluorouracil. External radiation began on day one using 1.5 daily fractions to 55.5 Gy. Intraluminal brachytherapy was delivered concomitantly once each week for 5 fractions of 4 Gy. None of the first eight patients went to surgery. The external radiation was changed to 1.5 Gy BID to 45 Gy followed by BID intraluminal radiation to 15 Gy. Of the last four patients, there was one case of radiation myelitis. It was found that successful surgery was not possible and excessive toxicities, including radiation myelitis, occurred with this aggressive regimen.

Original languageEnglish (US)
Pages (from-to)115-120
Number of pages6
JournalMedical Oncology
Volume12
Issue number2
DOIs
StatePublished - Jun 1995

Fingerprint

Esophageal Neoplasms
Radiation
Drug Therapy
Fluorouracil
Myelitis
interferon alfa-2b
Brachytherapy
Interferons
Radiotherapy
Carcinoma

Keywords

  • brachytherapy
  • esophageal cancer
  • high dose rate
  • hyperfractionation
  • interferon
  • intraluminal
  • radiation myelitis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer. / Beitler, Jonathan J.; Wadler, Scott; Haynes-Lewis, Hilda; Fell, Stanley; Rozenblit, Alla; Wolf, Ellen; Levine, Barry A.

In: Medical Oncology, Vol. 12, No. 2, 06.1995, p. 115-120.

Research output: Contribution to journalArticle

Beitler, Jonathan J. ; Wadler, Scott ; Haynes-Lewis, Hilda ; Fell, Stanley ; Rozenblit, Alla ; Wolf, Ellen ; Levine, Barry A. / Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer. In: Medical Oncology. 1995 ; Vol. 12, No. 2. pp. 115-120.
@article{885771707b4247e28e1716321155d564,
title = "Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer",
abstract = "A pilot study was performed to assess the feasibility of combining 5-fluorouracil, recombinant alpha-2b-interferon, external radiation therapy and intraluminal high dose rate brachytherapy with surgery in patients with locally advanced esophageal carcinoma. 5-fluorouracil, 750 mg m-2, was administered via continuous 5-day infusion beginning day 1 and weekly thereafter; interferon, 10 mu subcutaneously, was administered three times per week beginning day 1 and sargramostin, 5 μg kg-1, was administered on days without 5-fluorouracil. External radiation began on day one using 1.5 daily fractions to 55.5 Gy. Intraluminal brachytherapy was delivered concomitantly once each week for 5 fractions of 4 Gy. None of the first eight patients went to surgery. The external radiation was changed to 1.5 Gy BID to 45 Gy followed by BID intraluminal radiation to 15 Gy. Of the last four patients, there was one case of radiation myelitis. It was found that successful surgery was not possible and excessive toxicities, including radiation myelitis, occurred with this aggressive regimen.",
keywords = "brachytherapy, esophageal cancer, high dose rate, hyperfractionation, interferon, intraluminal, radiation myelitis",
author = "Beitler, {Jonathan J.} and Scott Wadler and Hilda Haynes-Lewis and Stanley Fell and Alla Rozenblit and Ellen Wolf and Levine, {Barry A.}",
year = "1995",
month = "6",
doi = "10.1007/BF01676712",
language = "English (US)",
volume = "12",
pages = "115--120",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer

AU - Beitler, Jonathan J.

AU - Wadler, Scott

AU - Haynes-Lewis, Hilda

AU - Fell, Stanley

AU - Rozenblit, Alla

AU - Wolf, Ellen

AU - Levine, Barry A.

PY - 1995/6

Y1 - 1995/6

N2 - A pilot study was performed to assess the feasibility of combining 5-fluorouracil, recombinant alpha-2b-interferon, external radiation therapy and intraluminal high dose rate brachytherapy with surgery in patients with locally advanced esophageal carcinoma. 5-fluorouracil, 750 mg m-2, was administered via continuous 5-day infusion beginning day 1 and weekly thereafter; interferon, 10 mu subcutaneously, was administered three times per week beginning day 1 and sargramostin, 5 μg kg-1, was administered on days without 5-fluorouracil. External radiation began on day one using 1.5 daily fractions to 55.5 Gy. Intraluminal brachytherapy was delivered concomitantly once each week for 5 fractions of 4 Gy. None of the first eight patients went to surgery. The external radiation was changed to 1.5 Gy BID to 45 Gy followed by BID intraluminal radiation to 15 Gy. Of the last four patients, there was one case of radiation myelitis. It was found that successful surgery was not possible and excessive toxicities, including radiation myelitis, occurred with this aggressive regimen.

AB - A pilot study was performed to assess the feasibility of combining 5-fluorouracil, recombinant alpha-2b-interferon, external radiation therapy and intraluminal high dose rate brachytherapy with surgery in patients with locally advanced esophageal carcinoma. 5-fluorouracil, 750 mg m-2, was administered via continuous 5-day infusion beginning day 1 and weekly thereafter; interferon, 10 mu subcutaneously, was administered three times per week beginning day 1 and sargramostin, 5 μg kg-1, was administered on days without 5-fluorouracil. External radiation began on day one using 1.5 daily fractions to 55.5 Gy. Intraluminal brachytherapy was delivered concomitantly once each week for 5 fractions of 4 Gy. None of the first eight patients went to surgery. The external radiation was changed to 1.5 Gy BID to 45 Gy followed by BID intraluminal radiation to 15 Gy. Of the last four patients, there was one case of radiation myelitis. It was found that successful surgery was not possible and excessive toxicities, including radiation myelitis, occurred with this aggressive regimen.

KW - brachytherapy

KW - esophageal cancer

KW - high dose rate

KW - hyperfractionation

KW - interferon

KW - intraluminal

KW - radiation myelitis

UR - http://www.scopus.com/inward/record.url?scp=0028847363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028847363&partnerID=8YFLogxK

U2 - 10.1007/BF01676712

DO - 10.1007/BF01676712

M3 - Article

C2 - 8535661

AN - SCOPUS:0028847363

VL - 12

SP - 115

EP - 120

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 2

ER -